There is great interest in targeting mTOR signaling pathways as a therapeutic approach for several diseases such as autoimmune disease, chronic inflammation and allograft rejection, and as an adjunct to cancer therapy (Saxton and Sabatini, 2017). The gene discussed is MTOR; the disease is cancer.